Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

Item

http://www.wikidata.org/entity/Q36475040

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@ast

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@en

type

Item

label

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@ast

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@en

prefLabel

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@ast

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@en

P1476

Influence of SLCO1B1 and CYP2C ...... kinetics in healthy volunteers

@en

P2093

Christina L Aquilante

http://www.w3.org/2001/XMLSchema#string

Lane R Bushman

http://www.w3.org/2001/XMLSchema#string

Lauren E Burt

http://www.w3.org/2001/XMLSchema#string

Lisa A Kosmiski

http://www.w3.org/2001/XMLSchema#string

Lucille Capo Rome

http://www.w3.org/2001/XMLSchema#string

Shannon D Knutsen

http://www.w3.org/2001/XMLSchema#string

P2860

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Sequence variation in PPARG may underlie differential response to troglitazone.

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

Thiazolidinediones.

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.

Transporters and drug therapy: implications for drug disposition and disease.

Transporters as a determinant of drug clearance and tissue distribution.

Pharmacogenomics of human OATP transporters.

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

P304

7-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-7364-3-1-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19129086

http://www.w3.org/2001/XMLSchema#string

P932

3525178

http://www.w3.org/2001/XMLSchema#string